首页> 美国卫生研究院文献>Cancers >Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series
【2h】

Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series

机译:IPF患者持续的系统审查和荟萃分析并在预期意大利现实案例系列中的持续持续持续载弹的串行变化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This paper is a review of the literature on the clinical role of oncomarkers in idiopathic pulmonary fibrosis (IPF) progression, and a description of the routine oncomarker trend in IPF patients over the longest follow-up yet reported. This is the first meta-analysis to review the results of studies evaluating the predictive prognostic value of circulating oncomarkers (CEA, Ca15.3, Ca19.9, Ca125, and KL-6) for IPF. The study focused on the discovery of multiple biomarker signatures, such as combinations of oncomarkers, that are widely and routinely available in biochemistry laboratories. The combination of clinical parameters and biological markers could help achieve more accurate results regarding prognosis and response to treatment in IPF. Our results could pave the way for a more “personalized” medical approach to patients affected by IPF.
机译:本文是对特发性肺纤维化(IPF)进展的临床作用的文献综述,以及在最长的随访中,IPF患者的常规持续趋势的描述。这是第一次审查研究结果评估IPF循环循环的预测预测值(CEA,CA15.3,CA19.9,CA125和KL-6)的预测性预后值。该研究专注于发现多种生物标志物签名,例如onComparers的组合,这些载体的组合在生物化学实验室中广泛而常规地提供。临床参数和生物标志物的组合可以帮助实现关于预后和对IPF治疗的准确结果。我们的结果可以为受IPF影响的患者提供更加“个性化”的医学方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号